UnternehmenThe company - Medical Strategy

In view of the spread of the coronavirus, the current risk situation associated with it, and the regulations of the German government, we implemented planned measures at an early stage to ensure that our business operations were fully operational. The full functionality of our systems and processes, as well as the readiness of our employees, is guaranteed even in the event of illness and/or quarantine measures. Currently, the majority of our employees work from home. Our infrastructure enables a home office quota of 100 percent, which means that all services can be provided in full at any time. This applies to all central processes. Our working methods and ability to act are therefore not restricted. Company and market analyses, portfolio management of the funds and trading are carried out without limits.

Medical Strategy is one of the leading independent healthcare investment advisers in Europe. In line with its core competence, the company focuses exclusively on managing and advising equity portfolios in the healthcare sector.

Company profile: download here.

Also in 2019 Medical Strategy was awarded with the FinanzResearch AWARD. In the segment of independent asset managers in Germany, the company was rated “Outstanding”. Medical Strategy ranked 9th among the top 100 independent asset managers. For further information please click here.

At the “Funds Europe Awards” in London in November 2018, Medical Strategy received a special commendation in the category “European Specialist Investment Firm of the Year”